Surveillance, Social Risk, and
Symbolism: Framing the Analysis for Research and Policy
http://www.managingdesire.org/hivsurv/burris.html
JAIDS Journal
of Acquired Immune Deficiency Syndromes 25:S120-S127 December, 2000
Lippincott Williams & Wilkins, Inc., Philadelphia
Scott Burris
Temple University Beasley School
of Law, Temple University, Philadelphia, Pennsylvania; and Center for
Law and the Public's Health, Georgetown and Johns Hopkins Universities,
U.S.A.
Summary: Name-based
surveillance for HIV, considered alone, is a useful public health
measure; its benefits outweigh its direct costs. There is little
evidence that name-based surveillance directly deters individuals at
risk of HIV from being tested, or exposes them to significant social
risks. Yet such surveillance is chronically controversial. Understood in
a broader context of the social risks and symbolic politics of HIV, as
subjectively experienced by people at risk, this opposition is both
rational and instructive. Although often discussed, the social risks of
HIV infection are poorly understood. To the extent these risks have been
addressed by privacy and antidiscrimination laws, the solution has been
less complete than many public health professionals appear to believe:
developments in law and policy, including the increasing prevalence of
criminal HIV transmission laws and proposed changes in HIV testing and
counseling standards, are contextual factors that help explain the
opposition to name-based surveillance. Rather than focusing piecemeal on
specific "barriers" to testing and care, an appreciation of the
surveillance debate in context suggests a positive undertaking in public
health policy to provide the conditions of opportunity, information,
motivation and confidence that people with HIV need to accept an
effective program of early intervention. Key Words: Criminal law-HIV
testing-HIV reporting-Confidentiality-Discrimination-Politics.
Name-based surveillance for HIV,
considered in and of itself, is a useful public health measure, the
benefits of which far outweigh direct costs. There is little evidence
that name-based surveillance directly deters individuals at risk of HIV
from being tested, or exposes them to significant social risks. Yet the
imposition of surveillance by name has been chronically controversial,
steadfastly opposed by HIV advocates, civil libertarians, and even some
public health professionals. This essay suggests that such opposition is
not only rational, but also instructive, and undertakes to reframe the
surveillance debate in order to draw out its useful lessons.
Name-based surveillance cannot be
properly considered, as a policy, by itself. Its significance is much
better appreciated in the context of the social risks and symbolic
politics of HIV, as these are subjectively experienced by people with
and at risk of HIV. Although often talked about, the social risks of HIV
infection are poorly understood. To the extent that these risks have
been addressed by privacy and antidiscrimination laws, the solution has
been less complete than many public health professionals appear to
believe: developments in law and policy, including the increasing
prevalence of criminal HIV transmission laws and proposed changes in HIV
testing and counseling standards, are environmental phenomena that help
explain the intensity of opposition to surveillance by name. This essay
proposes a holistic heuristic for practical prevention policy making.
Rather than focusing piecemeal on specific "barriers" to testing and
care, the surveillance debate counsels public health policy makers to
provide the conditions of opportunity, information, motivation, and
confidence that people with HIV need to accept an effective program of
early intervention.
THE SURVEILLANCE DEBATE: STANDARD
VERSION
With apologies for a certain amount
of oversimplification, conventional public health wisdom about the
name-based surveillance debate may be portrayed thus: name-based
surveillance is a useful public health too], but can be problematic when
applied to a disease like HIV, which is associated with distinct risks
such as breach of privacy, discrimination, and stigmatization. Although
name-based surveillance itself is safe, it can trigger individuals'
concerns about these other risks, and so counterproductively becomes a
barrier to testing, access to care, and other desirable health behavior.
Determining appropriate surveillance policy at any given time therefore
requires an assessment of whether the benefits of name-based
surveillance have sufficiently increased, and the risks been
sufficiently addressed, to change the risk benefit calculation in favor
of reporting names (1,2).
Within this framework, there is
quite a strong case to be made for named surveillance for HIV. The data
will help prevent disease, put money where it is needed, and could, at
least in theory (3), be used to help get people into care. Health
departments have an excellent record of maintaining confidentiality (2).
Name-based surveillance seems to have only a slight impact on testing,
particularly if anonymous testing remains an option (4-10). Indeed,
people being tested generally are not aware of the reporting
requirements that will apply to their results (11, 12). Laws protect
people from discrimination and breach of privacy. Given this strong
case, some public health professionals are frustrated by, and impatient
with, the continuing opposition to HIV reporting by name. They tend to
explain opposition as being based on misperceptions about the safety of
public health data. They suggest that opposition to name-based
surveillance is a relic of "AIDS exceptionalism," (13,14) arguing that
there are no longer good reasons for treating HIV "differently" from
other reportable diseases. To the extent that name-based surveillance
does pose risks to privacy, or of discrimination, they suggest that the
balance between individual rights and public health must in this
instance be adjusted toward the public health side.
THE LIMITS OF THE STANDARD
VERSION
The "standard version" is a good
analysis of name-based surveillance standing alone-but name-based
surveillance doesn't stand alone. To ask how name-based surveillance
influences individual behavior is to assume that "surveillance" is a
meaningful category in the behavioral decisions of individuals, and to
overlook the issue of how surveillance as both a practice and a policy
issue interacts with other phenomena in the social environment to
influence both individual behavior and social dispute. In the metaphor
of barriers, moreover, lurks the confounding assumption that the person
at risk was on the road to testing or care before name-based
surveillance interposed itself in her way, an assumption that
drastically oversimplifies the process and diverts attention from the
fundamental question of what makes people seek help on their own. If
name-based surveillance really is such a good idea for public health
(and so unlikely to harm people with HIV), then we may profitably focus
less on convincing opponents than on understanding why opposition
persists. Instead of asking how particular health practices such as
surveillance independently influence health behavior, we should begin to
look more broadly at the phenomenon of "social risk," and to study how
it is experienced by people with and at risk of HIV, how it influences
behavior, and how the social risks of HIV can effectively be reduced.
NAME-BASED SURVEILLANCE IN A
CONTEXT OF SOCIAL RISK
What should we take from the fact
that there is little or no opposition to name-based surveillance for
measles, Lyme disease, and tuberculosis, yet serious opposition to such
surveillance for HIV infection? One of the most important inferences to
be drawn is that name-based surveillance itself-the collection of
individually identifying data about the incidence or prevalence of a
disease in the population-is not a matter of controversy. It is not the
collection of names that is the problem, but the potential risks to
those whose names are collected. The risks are not medical; indeed, the
testing that produces the case report may often lead to medical
benefits. Rather, the risks are to the social and economic status of the
person being tested.
It has long been recognized that
having HIV, or even being regarded as at risk of HIV, can lead to
discrimination, stigmatization, and other socioeconomic harms (15). HIV
is a stigmatized condition, and those who have it are faced with a
certain amount of social hostility. The stigma and hostility are
magnified by the fact that HIV is spread by behavior that is itself
socially problematic: both drug use and homosexuality are independently
subject to stigma and social hostility (16). Surveillance by name is
just one practice that potentially poses such social risks. Others
include mandatory testing, partner notification, poor handling of
medical records, and criminalization of HIV-spreading behavior.
Despite the large role that social
risk has played in HIV policy, little is known about the influence of
social risk on behavior in the context of HIV. What is the incidence and
character of social mistreatment based on HIV? How do people who are
socially vulnerable because of HIV perceive their peril? How do
perceptions of social risk influence important health behavior? Are
current policies effective in reducing their fears or influencing their
behavior? There are too few good answers to these basic questions.
The main reason there are too few
answers is that we have too rarely asked the right questions. Asking how
particular policies influence HIV testing and other health behaviors
assumes that individuals are aware of and immediately responsive to
those policies. Such questions assume, that is, that "surveillance" and
"partner notification" and "criminal law" are meaningful analytic
categories for people at risk in the world. There are, however, good
reasons to doubt that most people categorize phenomena in the same terms
as public health professionals, researchers, and even politicians (17).
Conceivably there are people whose sole reason for not being tested is a
concern about name-based surveillance, but for most people surveillance
is probably bound up with other concerns about testing in complicated
ways. Recent research found that most people appearing for testing in
the studied states were actually unaware of the conditions of reporting
that obtained (11, 12). This does not mean that people who did not
appear at test sites were not deterred by name-based surveillance. It is
also quite possible for name-based surveillance to influence people who
do not know about it: concern about surveillance among social opinion
leaders or advocates could filter down to people at risk in the form of
less positive attitudes toward testing or greater anxiety about being
known to have HIV. All this simply illustrates how complex are the
mechanisms through which policies create social risk and influence
behavior. The key question is how people with and at risk of HIV
perceive the dangers of being tested or treated, and how those
perceptions influence behavior.
It may be useful to agree upon
terms. Social risk may be defined as the danger that an individual will
be socially or economically penalized should he or she become identified
with an expensive, disfavored, or feared medical condition. Social risk
may be seen to have two distinct components: (1) "the threat" (i.e., the
attitudes and behavior that cause or threaten social harm) and (2) "the
perception of risk" (i.e., the attitudes and beliefs about the threat
among those who are in some way tied to the trait or disease) (17,18).
Social risk, by hypothesis, will influence health behavior whenever the
social construction or economic cost of a disease creates the perception
of a risk that, alone or in combination with other factors, outweighs
the benefits of obtaining diagnostic or therapeutic care.
Adopting this framework helps
clarify several issues related to name-based surveillance. The
distinction between the threat and the perception of risk emphasizes
that the actual danger of harm coming from surveillance is largely
irrelevant; people's behavior is likely to be governed by the perceived
risk. The perception of risk, in turn, is the product of a set of
cognitive heuristics that are themselves not particularly sensitive to
actual probabilities of harm (19). In plain terms, people are afraid of
things that they are aware of, whose consequences strike them as
particularly unpalatable, and which they feel they cannot control.
Informing a person that there is very little chance of surveillance
information being released and causing harm is much like telling a
person afraid of flying that planes rarely crash. The risk assessment is
driven by the horror of the consequences, not their likelihood.
It is equally important to consider
that the perception of the risk may not be based purely, or even
substantially, in information about surveillance. People live in
context. Many people will not distinguish different parts of the
"system," and so may not see the helpful public health official as
distinct from the threatening legislator or policeman. They have had
experiences with doctors or with the health care system or with the
system generally. They tie name-based surveillance to other issues and
concerns, like racism or homophobia or social rejection (20).
A more comprehensive and nuanced
conception of social risk also raises serious concerns about how
policymakers and health care providers have responded to social risk.
There has been a tendency to think about social risks primarily in the
legal terms in which they first entered policy debate: breach of privacy
and discrimination. Unfortunately, a legal problem implies a legal
solution: if people are worried about privacy and discrimination, the
answer is to pass privacy and discrimination laws, and with their
passage the problem is solved. Passing such laws was a good idea, but
hardly a complete solution to social risk.
There are many social risks that law
does not address. It is illegal for an employer to fire a person because
he has AIDS, but it is not illegal for members of a church congregation
or other social group to shun him. A woman abandoned by her husband
because she has HIV has no discrimination claim. Even where law provides
a remedy in theory, it may not be effective in practice, as many victims
of domestic violence will attest (21). For many people, the eventual
remedy the law promises may not look substantial enough to overcome the
immediate fear of being banned; for example, a person whose
unwillingness to be tested arises from fear of losing job, benefits, and
social support may not be reassured by the possibility of winning money
damages at the end of several years of employment discrimination
litigation. And for some people, law is a hostile or alien force that is
either inaccessible or positively dangerous to encounter (22,23).
The limits of law as a way of
addressing social risk, together with sensitivity to social risk as a
cognitive phenomenon, have at least one very important implication for
prevention and clinical practice: public health workers and health care
providers can play a significant positive role in addressing social
risk. Laws can help make the social environment more favorable to
testing, but it is just as important to find ways to help individuals
better cope with both the threat and perception of social risk. A
provider can do much more to address a patient's social risk perceptions
than just warning her of the risks and informing her of the law in the
course of informed consent or counseling discussions. Indeed, merely
warning people that testing can be socially risky may actually make the
risk appear greater to the patient than it really is, or may cause the
patient to worry about the risks when she otherwise was comfortable with
testing, and telling people about legal protection may not be as
reassuring as the provider assumes. Securing informed consent to run a
risk, though important, is never a substitute for minimizing or
eliminating the risk. Along with information, the patient needs help in
addressing her perceived risks and making sensible choices about whether
the risk of testing or partner notification or health care outweighs its
benefits, help that counselors, case managers, and even physicians may
often be able to provide, and which will always be more accessible than
help from the legal system.
SOCIAL RISK AND NAME-BASED
SURVEILLANCE IN A POLITICAL CONTEXT
This essay has suggested that
name-based surveillance is just one of many sources of social risk, none
of which are necessarily perceived or assessed independently by people
making decisions about their behavior. A similar point can be made in
reference to name-based surveillance as a matter of social and political
dispute. Just as surveillance may not be experienced by people at risk
of HIV as a distinct source of social risk, so surveillance and social
risk themselves are not necessarily separable from a range of policy
disputes that affect the lives of people with and at risk of HIV, or the
political fortunes of their advocates. Name-based surveillance is a
tried, true, and valuable public health measure that in a perfect world
would have nothing to do with politics. In the inevitably political
world of public health (24), however, surveillance is just one chip in a
heated game of social and political poker.
Surveillance by name is an important
symbolic battle in a larger social struggle for status and power.
Sexually transmitted disease control policies have historically
reflected and been a vehicle for the expression of competing social
norms about sexual behavior and the status of women and minorities (25).
HIV stigma is still closely tied to homosexuality. Most heterosexual
Americans still associate HIV with homosexuality and bisexuality, and
HIV control has often been explicitly or implicitly tied to the
regulation of homosexuality (26). Surveillance rules, like mandatory
testing or criminal transmission laws, represent an assertion of social
control over those at risk of HIV, and their passage in a legislative or
administrative struggle often represents a victory for social factions
who not only believe that homosexuality and drug use are wrong, but also
that the toleration of these behaviors undermines their own values and
social status. Much political activity involves the gathering of such
symbolic spoils (27). On this view, name-based surveillance for HIV is
part of the same deeper struggle as laws prohibiting sodomy, or denying
civil rights protection to gay men and lesbians (28).
This is emphatically not to suggest
that public health proponents of named-based surveillance are homophobic
or intent on furthering any agenda other than better HIV prevention, but
only to note that such surveillance has a larger political dimension.
Nor are larger political motivations limited to some of those who favor
surveillance. The prevention of name-based surveillance or the use of
unique identifiers is an important symbolic victory for HIV advocates,
whose grass-roots support and future influence depends upon appearing to
influence policy. Privacy, moreover, is a perennially good advocacy
issue. It energizes the home base and it speaks to other people who
haven't really thought about the HIV issue. Surveillance by name is one
of the smallest privacy threats faced by people with HIV, but it is just
about the only privacy battle advocates feel they can win. Indeed, there
is a paradox here: advocates can go to the Centers for Disease Control (CDC)
or state health department and get serious consideration and even such
compromises as unique- identifier reporting. They cannot get an audience
with the medical information bureau, large managed care operations, or
pharmacy chains.
Perhaps most importantly, name-based
surveillance is a symbol of voluntarism in HIV control. The decision of
CDC in the early 1980s to favor a system of voluntary testing and
counseling, including anonymous testing, and generally not to call for
named HIV reporting, was the defining moment in the creation of a
fragile "voluntarist consensus" in HIV control (29). This consensus was
never complete, even in the federal government (30), but for all its
limitations, the idea that HIV prevention entailed cooperation, mutual
respect and protection against social risk has been an important one in
the development of HIV prevention, not just here but around the world
(31,32). The CDC's decision to revisit name-based surveillance is just
one of a series of events that raises the question of whether
voluntarism is and can remain at the heart of HIV policy, and it is in
this context that the controversy, and its possible effect on testing,
must be seen.
The use of criminal law as a means
of addressing HIV transmission continues to be a topic of debate, and a
matter of action. Thirty states have laws specifically criminalizing at
least some behavior that might spread HIV. The most narrow, like
California's, punish only deliberate use of HIV as a weapon to cause
harm through sex (33). Many are broader: Idaho's law, for example, makes
a criminal of anyone who "transfers or attempts to transfer" body fluid
in any way, knowing that he is infected (34). Given research findings
that a substantial proportion of people who know they are infected with
HIV sometimes engage in unsafe sexual or needle sharing behavior without
informing their partners of their infection (35), broad laws like
Idaho's make most people with HIV into potential targets of prosecution.
Criminalization also endangers
confidence in the privacy of public health records. There are reported
instances of law enforcement personnel seeking health department testing
or treatment records in order to establish that a defendant was aware of
being HIV-infected at the time of the allegedly criminal act (36). Even
if rare, such events have the potential to resonate widely among those
at risk, as happened in the case of a health department worker in
Florida who improperly released HIV records (37). Any use of public
health data for law enforcement purposes represents a profound threat to
public health, because it compromises the principle that public health
data are sacrosanct for any purpose other than public health.
Privacy, never robust in health
practice, has become even more at risk. Although another legislative
season has now passed without federal action, some of the bills proposed
in Congress last year would essentially have stripped out the heightened
protection for HIV confidentiality in state law. The CDC's Model State
Public Health Privacy Act (38) is an important proactive initiative, and
would protect records in public health hands, but it would have to be
passed by fifty states and could still be overridden by Congress. More
importantly, it does not apply to HIV records in private hands, where
the most damage tends to arise.
Nor can one justly feel sanguine
about the national commitment to nondiscrimination on the basis of HIV.
The Supreme Court did rule that a person with asymptornatic HIV can be
considered disabled under the Americans with Disabilities Act (39). The
Court did not rule that every person with HIV is to be deemed disabled,
and the justices were divided almost evenly on what is known as the
"direct threat" issue: when discrimination is justified because the
person with HIV poses a significant risk to others. In the lower courts,
there have been several cases that recall the worst days of the early
epidemic: a man fired from his job in the produce section of a market
because he refused to submit to a test for HIV (40); a child with HIV
kept out of a karate class (41); a family not permitted to provide
foster care because one child already in the family has HIV (42). All
these patently unnecessary acts of discrimination were upheld by courts
at least in part on the ground that they were justified by the risk of
transmission.
The most dangerous threat to
voluntarism has been the suggestion that prior informed consent for
testing for pregnant women be replaced by what is euphemistically called
an "informed right of refusal" (43). The proposal is a response to the
widespread unwillingness of obstetricians to offer HIV tests, which is
blamed on the supposedly onerous requirements of counseling and informed
consent enshrined in testing guidelines and state HIV testing laws. This
proposal exemplifies the problem of narrow framing. By focusing on the
obstetrical setting, and looking for an expeditious way to address
obstetricians' concerns, proponents of the informed right of refusal
approach have underestimated the overall costs of the change, and failed
to consider cheaper alternatives.
There is little or no evidence that
the requirement of prior written consent retards testing other than by
deterring the provider from making the offer. In fact, testing
guidelines could be changed to make testing easier for health care
providers to offer without eliminating explicit prior consent. There is,
for example, no need for full risk-reduction counseling in the prenatal
setting, where the purpose of testing is to provide medical care and
prophylaxis. Likewise, the specific requirements imposed by state law
have been exaggerated: as a general matter, state testing laws require
no more than that patients get some sort of written or oral information
about the test, and the opportunity to sign a specific consent form,
before being tested. In practice, then, HIV testing statutes do not
forbid making the offer of testing "routine," nor do they preclude
counseling that emphasizes the benefits of testing or that replace oral
with written information. Provider motivation to test is very important,
but there are more ways to deal with it than just by reducing patient
control (44,45).
The reason to look for alternatives
is clear when one looks beyond the obstetrician's office. The move away
from prior explicit consent poses an enormous threat to the structure of
HIV privacy law in this country. State HIV testing laws do not require
much in the way of specific behavior, but they do generally require a
signature on a specific release before a test may be performed.
Lazzarini and colleagues have examined the potential impact of a change
to an "opt-out" system, and have preliminarily determined that more than
thirty states would have to change their state laws to allow it. (oral
communication, Vita Lazzarini, J.D., MPH., March 2000).
The prospect of states revisiting
their basic HIV confidentiality laws is one that anyone concerned with
voluntarism should view with alarm. The coalitions and conditions that
produced these laws during the mid to late 1980s are not necessarily
present today. There is no guarantee that legislatures would restrict
the change to pregnant women, and organizing and finding the resources
to fight a new battle over the basic rules of HIV testing and privacy
would be an enormous challenge for public health, HIV, and civil
liberties advocates. If we can increase prenatal testing rates without
eliminating prior written consent, a broader view of the state of
voluntarism suggests making a serious effort to do so.
Recognizing the symbolic dimensions
of surveillance can be practically useful to policy makers. It shows,
for one thing, that as with individual behavior, the problem is not
necessarily name-based surveillance itself. Opposition to name-based
surveillance, that is, is to some degree a sort of referred pain from
other injuries, and there is at least some room to advance name-based
surveillance by paying more attention to those other problems. If the
"problem" is deep concern about voluntarism, public health officials can
couple support for name-based surveillance with measures to enhance
privacy and discrimination protection in the law, and to increase
patient protection in the testing process. They can be heard more
strongly in the criminalization debate. They can move from justifying
name-based surveillance on the basis of an end to exceptionalism to
emphasizing the continuing need to address both the threat and
perception of social risk. None of this represents a resolution to the
political debate about surveillance, but such a resolution is hardly
realistic: politics is a process; a better understanding of the inputs
to the process will usually lead to better, if imperfect, outputs.
REFRAMING THE DISCUSSION: FROM
BARRIERS TO CONDITIONS
The unstated premise of this essay
has been the importance of cognitive heuristics, not just in day-to-day
life but also in policy-making and research. Just as individuals use
mental short cuts to assess their social risks, so policy-makers and
researchers rely on accepted metaphors and analytic categories to set
their agendas. Heuristics are at once necessary, useful and, by
definition, limiting (46). In the debate over surveillance, there has
been a tendency to conceptualize name-based reporting as a meaningfully
distinct practice and to ask whether by itself it operates as a barrier
to testing and other early intervention strategies. This essay has
discussed the limits of this sort of mental and rhetorical shorthand,
and how it has hurt the debate.
A new heuristic may be helpful, one
that takes a more holistic approach to assessing the interrelationship
of policies, social conditions, incentives and disincentives to testing,
and other elements of an early intervention regime. Testing rates depend
upon social risks, but also upon cost, convenience, perceived benefits,
and the usual psychological processes triggered by the prospect of
diagnosis with a fatal disease (47).
Rather than relying on the metaphor
of barriers to early intervention, this essay suggests taking a page
from the Institute of Medicine's definition of the mission of public
health: creating the conditions in which people can be healthy (48). An
early intervention policy, regardless of its specific components, will
succeed only if it creates a climate in which people with and at risk of
HIV have (1) the opportunity to obtain testing and other services; (2)
the information necessary to assess and fulfill their needs; (3) the
motivation to use the information and take up the opportunity; and (4)
the confidence to run the real and perceived risks entailed in doing so.
HIV prevention efforts have done
very well in providing opportunities for and information about HIV
testing. Motivation has historically been harder to foster (49,50). Real
access to better treatment options could be an important motivator, but
for too many people, knowing one's HIV status is still just less
important than other issues on the survival agenda.
"Confidence" could well be seen as
simply an aspect of motivation, but for heuristic purposes it is useful
to treat it as distinct. It evokes the individual's affective analysis
of his or her situation, but at the same time is intended to suggest the
need for collective social action: instilling confidence in the person
at risk requires that individual clinicians and other health and service
providers help people at risk to have the faith that something positive
can come out of being tested, and also that we "change the world" to
make testing and early intervention safer in the first place. As
Freudenberg wrote: "The reality is that a world without AIDS, or a world
with this epidemic under control, will look very different. AIDS
educators need to help people visualize this world and connect their
daily lives to making it happen. It will be a world where every one is
entitled to comprehensive education about sexuality, drugs, and health;
a world where those who need treatment for drug addiction can get it on
demand; a world where basic health care is a right, not a privilege; a
world where gay men and lesbians, women and people of color, are not
discriminated against; a world where alternatives to drug use exist for
the young people of this country; a world where no one has to die on the
streets because there is no home for them" (51).
CONCLUSION
A review of the name-based
surveillance controversy shows that we still have much to learn about
how individuals cope with the prospect of being diagnosed with HIV, and,
more importantly, requires us to examine the social environment in which
surveillance and testing are experienced, and in which policy is made.
If we can understand the logic of the surveillance debate, we can get a
better sense of what we need to know about how our society structures
the experience of the disease in ways that can enhance, or hinder,
prevention. Regardless of the outcome of the current policy dispute (1),
the conditions that make name-based surveillance a sensitive issue will
remain, and remain important to understand.
Acknowledgments: The author thanks
Kevin De Cock, Ron Valdiserri and the anonymous reviewers for their
challenging comments, and Lionel Artom-Ginzburg for assistance in
research and manuscript preparation.
Address correspondence and reprint
requests to Scott Burris, J.D.,
Temple University Beasley School of Law, Temple University,
1719 N. Broad Street, Philadelphia, PA 19122;
e-mail: Burris@vm.temple.edu
REFERENCES
1. Centers for Disease Control.
Guidelines for national human immunodeficiency virus case surveillance,
including monitoring for human immunodeficiency virus infection and
acquired immunodeficiency syndrome. MMWR 1999;48(RR-13):1-31.
2. Gostin LO, Ward JW, Baker AC.
National HIV case reporting for the United States: a defining moment in
the history of the epidemic. N Engl J Med 1997;337:1162-7.
3. Osmond DH, Bindman AB, Vranizan K
et al. Name-based surveillance and public health interventions for
persons with HIV infection. Ann Intern Med 1999;131:775-9.
4. Fehrs LJ, Fleming D, Foster LR,
et al. Trial of anonymous versus confidential human immunodeficiency
virus testing. Lancet 1988; 2:379-82.
5. Hirano D, Gellert GA, Fleming K,
Boyd D, Englender SJ, Hawks H. Anonymous HIV testing: the impact of
availability on demand in Arizona. Am J Public Health 1994;84:2008-10.
6. Hoxworth T, Hoffman R, Cohn D,
Davidson A. Anonymous HIV testing: does it attract clients who would not
seek confidential testing? AIDS Public Policy J 1994;9:182-89.
7. Meyer PA, Jones JL, Garrison CZ,
Dowda H. Comparison of individuals receiving anonymous and confidential
testing for HIV, Southern Med J 1994;87:344-47.
8. Hertz-Picciotto 1, Lee LW, Hoyo
C. HIV test-seeking before and after the restriction of anonymous
testing in North Carolina. Ain J Public Health 1996;86:1446-50.
9. Kassler WJ, Meriwether RA, Klimko
TB, Peterman TA, Zaidi A. Eliminating access to anonymous HIV antibody
testing in North Carolina: effects on HIV testing and partner
notification. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:281-9.
10. Woods WJ, Dilley JW, Lihatsh T,
Sabatino J, Adler B, Rinaldi J. Name-based reporting of HIV-positive
test results as a deterrent to testing. Am J Public Health
1999;89:1097-100.
11. Nakashima AK, Horsley RM, Frey
RL, Sweeney PA, Weber JT. Fleming PL. Effect of HIV reporting by name on
use of HIV testing in publicly funded counseling and testing sites. JAMA
1998: 280:1421-6.
12. Lansky A, Lehman JS, Gatwood J,
Hecht F, Fleming PL. Change in HIV testing patterns after implementation
of name-based HIV case surveillance in New Mexico [abstract TuOrC31 I].
Presented at the XIII International AIDS Conference, July 2000, Durban,
South Africa.
13. Bayer R. Public health policy
and the AIDS epidemic: an end to HIV exceptionalism? N Engl J Med
1991;324:1500-4.
14. Burris S. Public health, "AIDS
exceptionalism" and the law. John Marshall L Rev 1994;27:251- 272.
15. Institute of Medicine.
Confronting AIDS. Washington, DC: Na-tional Academy Press, 1986.
16. Herek GM. AIDS and stigma. Am
Behavioral Scientist 1999;42: 1106-16.
17. Burris S. Law and the social
risk of health care: lessons from HIV testing. Albany L Rev
1998;61:831-95.
18. Burris S. Driving the epidemic
underground? A new look at law and the social risk of HIV testing. AIDS
Public Policy J 1997; 12: 66-78.
19. Kahnemann D, Slovic P, Tversky
A, eds. Judgment under uncertainty: heuristics and biases. Cambridge,
UK: Cambridge Univer. ty Press;] 982.
20. Weitz R. Uncertainty and the
lives of persons with AIDS. J Health Soc Behavior 1989;30:270-81.
21. Bernstein, SE. Living under
siege: do stalking laws protect domes-tic violence victims? Cardozo L
Rev 1993; 15:525-67.
22. Ewick P, Silbey S. The common
place of law. Chicago, IL: Uni-versity of Chicago Press; 1998.
23. Musheno MC. Legal consciousness
on the margins of society: struggles against stigmatization in the AIDS
crisis. Identities 1995: 2:102-22.
24. Gostin LO, Burris S, Lazzarini
Z. The law and the public's health: a study of infectious disease law in
the United States. Columbia L Rev 1999;99:59-128.
25. Brandt, AM. No magic bullet: a
social history of venereal disease in the United States since 1880. New
York: Oxford Universit) Press; 1987.
26. Herek GM, Capitano JP. AIDS
stigma and sexual prejudice. Am Behavioral Scientist 1999;42:1130-47.
27. Gusfield JR. Symbolic crusade:
status politics and the American temperance movement. Urbana, IL.:
University of Illinois Press; 1963.
28. Dangerous Bedfellows, eds.
Policing public sex: queer politics and the future of AIDS activism.
Boston: South End Press; 1996.
29. Bayer R. Private acts, social
consequences: AIDS and the politics of public health. New York: Free
Press; 1989.
30. Burris S. Studying the legal
management of HIV-related stigma. Am Behavioral Scientist
1999;42:1229-43.
31. Gostin LO, Lazzarim Z. Human
rights and public health in the AIDS pandemic. Oxford: Oxford University
Press: 1997.
32. Mann JM. Medicine and public
health, ethics and human rights. Hastings Center Rep 1997;May-June:6-13.
33. Cal. Health & Safety Code §
12029 1.
34. Idaho Code §39-608.
35. Mark G, Burris S, Peterman T.
Reducing sexual transmission of HIV from those who know they are
infected: the need for personal and collective responsibility. AIDS
1999; 13:297-306.
36. Commonwealth v. Moore, 526 Pa.
152, 584 A.2d 936 (1991).
37. Associated Press. Ex-AIDS worker
pleads no contest in privacy case. Orlando Sentinel. September 25,
1997;D8.
38. Gostin LO, Hodge JG. Model state
public health privacy act.Washington, DC: Georgetown University, 1999.
39. Bragdon v. Abbott, 524 U.S. 624
(1998).
40. Equal Employment Opportunity
Commission v. Prevo's Family Market, Inc., 135 F.3d 1089 (6th Cir.
1998).
41. Montalvo v. Radcliffe, 167 F.3d
873 (4th Cir. 1999).
42. Doe v. County of Centre, 60
F.Supp.2d 417 (M.D.Pa.,1999).
43. Institute of Medicine Committee
on Perinatal Transmission of HIV. Reducing the odds: preventing
perinatal transmission of HIV in the United States. Washington, DC:
National Academy Press; 1998.
44. Joo E, Carmack A, Garcia-Bunuel
E. Kelly CJ. Implementation of guidelines for HIV counseling and
voluntarv HIV testing of pre--nant women. Am J Public Health
2000;90:273-76.
45. Phillips KA, Morrison KR, Sonnad
SS, et al. HIV counseling and testing of pregnant women and women of
childbearing age by primary care providers: self-reported beliefs and
practices. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:174-78.
46. Burris S. The invisibility of
public health: population-level measures in a politics of market
individualism. Am J Public Health 1997;87:1607-10.
47. Phillips KA, Coates TJ. HIV
Counseling and testing: research and policy issues. AIDS 1995;7:115-24.
48. Institute of Medicine, National
Academy of Sciences. The.future of public health. Washington, DC:
National Academy Press; 1988:40.
49. Povinelli M, Remafedi G, Tao G.
Trends and predictors of human immunodeficiency virus antibody testing
by homosexual males, 1989-1994. Arch Pediatr Adolesc Med 1996; 150:33.
50. Choi KH, Catania JA. changes in
multiple sexual partnerships, HIV testing and condom use among U.S.
heterosexual men 19-49 years of age, 1990-1992. Am J Public Health
1996;86:554.
51. Freudenberg N. AIDS prevention
in the United States: lessons from the first decade. Int Health Services
1990;20:590-98.
|